Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
An immunotoxin containing an anti-CD30 monoclonal antibody (Ber-H2) and saporin, a ribosome-inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50 ranging from 5 x 10(-12) M to 5 x 10(-14) M, as saporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used for in vivo therapy as well as for ex vivo bone marrow purging in Hodgkin's disease and CD30+ lymphomas.
Tazzari
P L
PL
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Bolognesi
A
A
de Totero
D
D
Falini
B
B
Lemoli
R M
RM
Soria
M R
MR
Pileri
S
S
Gobbi
M
M
Stein
H
H
Flenghi
L
L
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002460:Cell Line; D004354:Drug Screening Assays, Antitumor; D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D017730:Ki-1 Antigen; D008223:Lymphoma / Q000628:therapy*; D051379:Mice; D009699:N-Glycosyl Hydrolases; D010940:Plant Proteins / Q000627:therapeutic use*; D054789:Ribosome Inactivating Proteins, Type 1; D012276:Ricin; D000076985:Saporins
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000972:Antineoplastic Agents, Phytogenic; D000922:Immunotoxins; D017730:Ki-1 Antigen; D010940:Plant Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D012276:Ricin; D009699:N-Glycosyl Hydrolases; D000076985:Saporins